Stock Strategist

We Like Zimmer's Pick for CEO

Debbie S. Wang

We’re pleased with  Zimmer Biomet’s (ZBH) choice of president and CEO, and we’re leaving our fair value estimate and wide economic moat rating unchanged.

Bryan Hanson most recently ran the minimally invasive therapies group at Medtronic (MDT). While he is new to the orthopedic market, on balance, we think he’ll bring to Zimmer Biomet a much-needed new perspective and an appetite to try different ideas.

Debbie S. Wang does not own shares in any of the securities mentioned above. Find out about Morningstar's editorial policies.